UroGen Pharma to Present at Upcoming Investor Conferences
URGNPRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
URGNNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN
URGNNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. (UroGen Pharma Ltd. or the Company) (NASDAQ: URGN) of a class action securities lawsuit.
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN
URGNNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. (UroGen Pharma Ltd. or the Company) (NASDAQ: URGN) of a class action securities lawsuit.
Trading Halt: Halt status updated at 1:55:00 PM ET: Quotation Resumption: News and Resumption Times
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNFDA Approves UroGen's ZUSDURI For Intravesical Solution As Medication For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
URGNU.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
URGNPRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen’s proprietary sustained release RTGel® technology. ZUSDURI has been designed
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
URGNPRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen’s proprietary sustained release RTGel® technology. ZUSDURI has been designed
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN
URGNNEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN
URGNNEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).
Trading Halt: Halted at 11:56:54 a.m. ET - Trading Halt: Halt News Pending
URGNOppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $10
URGNUroGen Pharma Highlights Presentation Of uTRACT Registry Study Design At 2025 ASCO Annual Meeting
URGNUroGen Pharma Announces Results From ENVISION And ATLAS Clinical Studies Exploring Investigational Therapy UGN-102 For Intravesical Solution For Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
URGNUroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
URGNAnalyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.
Goldman Sachs Maintains Neutral on UroGen Pharma, Lowers Price Target to $3
URGNHC Wainwright & Co. Downgrades UroGen Pharma to Neutral
URGNWhat's Going On With UroGen Pharma Stock Wednesday?
URGNUtroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.
UroGen Pharma Shares Resume Trade
URGNTrading Halt: Halt status updated at 12:50:00 PM ET: Quotation Resumption: News and Resumption Times
URGNUroGen Announces Outcome Of ODAC For UGN-102 For Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
URGNTrading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
URGNHC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $55 Price Target
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNUroGen Pharma Q1 2025 EPS $(0.92) Misses $(0.78) Estimate, Sales $20.25M Miss $22.80M Estimate
URGNA Look at UroGen Pharma's Upcoming Earnings Report
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNUroGen Announces FDA Advisory Committee For UGN-102
URGNGuggenheim Reiterates Buy on UroGen Pharmato Buy
URGNUroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
URGNUroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $55 Price Target
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNReported Sunday, UroGen Highlights Nearly Four-Year Duration Of Response In OLYMPUS Long-Term Follow-Up Study Of JELMYTO
URGNReported Sunday, UroGen Presents New Data Showing UGN-102 Does Not Adversely Affect Functionality or Symptom Burden
URGNReported Sunday, UroGen's OPTIMA II Study Results Show UGN-102 Delivers Median 24.2-Month Duration Of Response In Recurrent LG-IR-NMIBC
URGNReported Saturday, UroGen Pharma's UGN-102 Achieves 80.6% Probability Of Sustained Complete Response At 18 Months In Phase 3 ENVISION Trial
URGNReported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer
URGNGoldman Sachs Maintains Neutral on UroGen Pharma, Lowers Price Target to $16
URGNScotiabank Initiates Coverage On UroGen Pharma with Sector Outperform Rating, Announces Price Target of $23
URGNUroGen To Present At American Urological Association 2025 Annual Meeting Apr. 26 and 27
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNHC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $55
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNUroGen Reported Updated 18-month Duration Of Response Data From The Phase 3 Envision Trial Of UGN-102 For Low-grade Intermediate Risk Non-muscle Invasive Bladder Cancer, With A DOR Rate Of 80.6% At 18-months Compared To 82.5% At 12-months
URGNUroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate
URGNHC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $64 Price Target
URGND. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNAs Consideration For Assets, UroGen Issued IconOVir 374,843 Of Its Ordinary Shares, Agreed To One-Time Payment Of $15M Upon Milestones And A Low Single-Digit Royalty Percentage
URGNUroGen Acquires Assets Relating To ICVB-1042 From IconOVir
URGN